This extends the scope of potential applications of GSK3β inhibitors and suggests that chronic administration of GSK3β inhibitors maybe an option for treating behavioral and cognitive deficits associated with adolescent METH abuse in adulthood. Here, GSK3B is linked to Cognitive impairment.